Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.64 per share a year ago.

Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts

DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her

• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026 • DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options • Award reflects Daré's strategy of leveraging non-dilutive grant funding to advance a deep, differentiated pipeline addressing the most persistent unmet needs in women's health

Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical study, and what the program could mean for women's health Access the segment here

DARE-HPV development supported by $10 million ARPA-H contract; program targets major unmet need with no FDA-approved therapies DARE-HPV development supported by $10 million ARPA-H contract; program targets major unmet need with no FDA-approved therapies